NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 02/01/2010 08:30
Last Report Issued 09/28/2009 14:00

88888
Clinical Dummy reports
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

Patient Name 2512SP-POS
Patient ID 2512SP-POS
Chain 1
Age Not Given **Gender** Not Given

Workorder 09003119

Received 09/28/2009 13:49

Sample ID 09003119-001
Matrix Serum or Plasma
Patient Name 2512SP-POS
Patient ID 2512SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2512SP Lidocaine and Metabolite (MEGX), Serum/Plasma				
Analysis by Gas Chromatography (GC)				
Lidocaine	12	mcg/mL	0.50	ELEVATED
Synonym(s): Xylocaine®				
Reported antiarrhythmic range: 2 - 5 mcg/mL.				
Diphenhydramine interferes with lidocaine in this analysis. The presence of diphenhydramine will adversely affect the quantitation of lidocaine. If diphenhydramine is a potential interferent in this case, call the laboratory for alternate quantitative procedures.				
Monoethylglycinexylidide (MEGX)	12	mcg/mL	0.50	ELEVATED
Synonym(s): Lidocaine Metabolite				
Following a Lidocaine I.V. infusion at rates varying between 20 and 50 mcg/min/kg, steady-state MEGX serum concentrations range from 0.2 - 5.2 mcg/mL.				